|1.||Alberts, Steven R: 2 articles (01/2007 - 06/2002)|
|2.||Suman, Vera J: 2 articles (01/2007 - 06/2002)|
|3.||Rubin, Joseph: 1 article (01/2007)|
|4.||Pitot, Henry C: 1 article (01/2007)|
|5.||Camoriano, John K: 1 article (01/2007)|
|6.||Leitch, John M: 1 article (06/2002)|
|7.||Vukov, Allen M: 1 article (06/2002)|
|8.||Kaur, Judith S: 1 article (06/2002)|
|9.||Fitch, Tom R: 1 article (06/2002)|
|10.||Markovic, Svetomir N: 1 article (06/2002)|
01/01/2007 - "KW-2189 showed evidence of anti-tumor activity in HCC. "
05/01/1994 - "Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors."
05/01/1994 - "The most remarkable feature of KW-2189 was its efficacy against various human xenografts, which was observed in 14 tumors among 16 tested tumors including drug-insensitive tumors by single i.v. administration. "
09/01/1998 - "We conducted a Phase I trial of KW-2189 in patients who had solid tumors that were refractory to standard chemotherapy or for whom no more effective therapy existed. "
06/01/2002 - "KW-2189, a semisynthetic duocarmycine antibiotic has been shown to exert antiproliferative effects against human tumor cell lines in vitro and animal tumor models in vivo. "
|4.||Melanoma (Melanoma, Malignant)
06/01/2002 - "Presented are two concurrent phase II studies assessing the antitumor and toxicity profile of KW-2189 in metastatic melanoma patients. "
06/01/2002 - "In summary, the lack of significant antitumor activity of KW-2189 and its associated toxicity suggest that further testing of this regimen in patients with stage IV melanoma is not warranted."
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
04/01/1994 - "Cytotoxic activity was examined by exposing a human small cell lung cancer cell line, NCI-H69 to KW-2189 with or without carboxyl esterase. "
04/01/1994 - "A novel antitumor antibiotic, KW-2189 is activated by carboxyl esterase and induces DNA strand breaks in human small cell lung cancer cells."
01/01/1995 - "Three duocarmycins, KW-2189, DU-86 and duocarmycin SA, were active against the cisplatin (CDDP)-resistant human non-small cell lung cancer cell lines PC-9/CDDP and PC-14/CDDP, and the multidrug-resistant human small cell lung cancer cell line H69/VP. "
|1.||procollagen Type I N-terminal peptide (P-I-P)
|6.||A-Form DNA (A-DNA)
|7.||DNA (Deoxyribonucleic Acid)
|8.||Caffeine (No Doz)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)